Merck & Co., Inc. stock sees Citigroup price target hike amid Keytruda momentum and analyst optimism

Citigroup raised its price target on Merck & Co., Inc. (ISIN: US58933Y1055) to $125 from $120 while maintaining a Neutral rating, signaling moderate upside potential. This adjustment reflects growing confidence in the company's oncology portfolio, particularly Keytruda, as recent analyst actions cluster around positive revisions. For DACH investors, the stock offers defensive healthcare exposure with US market strength amid European pharma headwinds.

Merck & Co., Inc. shares drew fresh attention after Citigroup analyst Geoff Meacham raised the price target to $125 from $120 on March 20, 2026, while keeping a Neutral rating. This 4.17% increase underscores steady optimism for Merck's blockbuster oncology drug Keytruda and its broader pipeline, even as the firm navigates patent cliffs ahead. The move aligns with a wave of recent upgrades from peers like Wells Fargo and Guggenheim, pointing to expected revenue resilience in 2026.

As of: 21.03.2026

By Dr. Elena Hartmann, Senior Pharma Equity Analyst – Tracking US biotech leaders' pipeline execution and European market spillovers for DACH portfolios amid global drug pricing dynamics.

Analyst Momentum Builds on Keytruda Strength

Citigroup's adjustment caps a series of bullish calls on Merck & Co., Inc. Wells Fargo lifted its target to $150 from $135 just days earlier on March 12, maintaining Overweight. Guggenheim followed suit in February, pushing to $140 with a Buy rating. These revisions highlight Keytruda's sustained dominance in immuno-oncology, contributing over 40% of Merck's revenue as the leading PD-1 inhibitor.

The stock trades on the NYSE in USD, where it has shown resilience amid broader market rotations. Recent institutional buying, such as Park National Corp's 135% stake increase in Q4 2025 to 111,325 shares worth about $11.72 million, adds conviction. Consensus now points to an average target of $127.84 from 28 analysts, implying over 12% upside from recent levels around $113.74.

Keytruda's label expansions into new cancers and combinations continue driving growth. Merck's Q4 earnings beat expectations, with oncology sales up double-digits year-over-year. Vaccines like Gardasil also bolster the top line, with HPV prevention demand strong globally.

Pipeline Catalysts Fuel Price Target Revisions

Beyond Keytruda, Merck's pipeline advances provide the core rationale for these targets. The company boasts over 80 programs in clinical development, spanning oncology, vaccines, and cardiometabolic therapies. Recent Phase 3 data readouts have de-risked several assets, including next-gen HPV vaccines and antibody-drug conjugates.

Winrevair, Merck's recently launched pulmonary arterial hypertension drug, ramps up with strong early uptake. Animal health remains a steady contributor, less cyclical than human pharma. Geographically, 47% of sales stem from US human health, insulating against European pricing pressures that hit DACH peers harder.

Wall Street's 'Outperform' consensus (rating 2.1/5) reflects this balance. High-end targets at $150 suggest blockbuster potential if pipeline hits mature. Merck's R&D spend, around 30% of sales, supports sustained innovation versus generics erosion.

Why DACH Investors Should Monitor Merck Closely

For German, Austrian, and Swiss investors, Merck & Co., Inc. stock offers a compelling defensive play in portfolios heavy on European pharma. While local giants like Roche or Bayer grapple with pricing reforms and regulatory scrutiny, Merck benefits from US-centric revenue and robust IP protection. Keytruda's global dominance translates to steady euro-denominated dividends, appealing amid DACH yield hunts.

Europe accounts for about 25% of Merck's sales, with oncology demand aligned to aging demographics in Germany and Switzerland. DACH funds have upped US healthcare allocations, viewing Merck as a hedge against regional biosimilar competition. The NYSE-listed shares (ISIN US58933Y1055) trade liquidly via local brokers, with currency hedging straightforward.

Recent analyst upgrades resonate locally, as Handelsblatt and FAZ coverage highlights Merck's outperformance versus STOXX Europe 600 Health Care. Institutional flows from Allianz and Zurich Insurance into MRK underscore this trend.

Financial Backbone Supports Long-Term Growth

Merck's balance sheet remains fortress-like, with investment-grade ratings and ample cash for buybacks and M&A. Free cash flow covers dividends comfortably, yielding around 3% at current levels on NYSE in USD. Debt levels are manageable post-Keytruda investments, with net debt-to-EBITDA under 2x.

Growth guidance centers on mid-single-digit revenue expansion through 2030, driven by 20+ potential launches. Margins hold steady at 40%+ gross levels, buffering R&D escalation. Compared to peers, Merck's ROIC exceeds 15%, reflecting efficient capital allocation.

Q1 2026 previews suggest Keytruda sales topping $7 billion quarterly, with Gardasil nearing peak. Animal health spin-off options remain on table, unlocking value.

Key Risks and Patent Horizon Challenges

Keytruda's US patent expiry in 2028 looms large, potentially eroding $25 billion+ annual sales. Biosimilars could capture share rapidly, pressuring margins. Merck counters with a $10 billion+ pipeline to fill the gap, but execution risks persist in late-stage trials.

Regulatory hurdles, especially FDA oncology approvals, add volatility. Macro factors like US drug pricing reforms under potential new administrations weigh on sentiment. Competition intensifies from Regeneron and Bristol Myers in immuno-oncology.

Forex exposure impacts DACH holders, with USD strength boosting returns but volatility a concern. Supply chain issues in vaccines linger post-pandemic.

Strategic Positioning for 2026 and Beyond

Merck accelerates M&A in ADCs and radiopharma, complementing internal R&D. Partnerships with Daiichi Sankyo on patritumab deruxtecan exemplify this. Vaccines franchise eyes RSV and next-gen flu shots for blockbuster status.

Sustainability efforts, including net-zero goals by 2050, align with European ESG mandates, aiding DACH fund inclusion. Share repurchases pace at $4 billion annually supports EPS growth.

For conservative DACH investors, Merck blends growth and defense, with analyst targets signaling 10-15% upside. Monitoring Q1 earnings will clarify trajectory.

Investment Case in DACH Context

DACH portfolios favor Merck for its scale versus smaller biotechs. Dividend aristocrat status, 50+ years increasing payouts, suits income strategies. Versus Novartis or Sanofi, Merck's US growth edge shines.

Local analysts echo global optimism, with DZ Bank and Vontobel citing pipeline depth. ETF inclusion via MSCI World boosts accessibility. Overall, the Citigroup hike reinforces Merck's premium positioning amid pharma sector rotations.

Disclaimer: This is not investment advice. Stocks are volatile financial instruments.